---
title: "Economic value of gonorrhea resistance testing in the US: multi-perspective model"
id: "pubmed-43043955"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43043955"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43043955/"
doi: "10.1371/journal.pmed.1005073"
published_at: "2026-11-17T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Economic value of gonorrhea resistance testing in the US: multi-perspective model
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43043955
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43043955/)
- **DOI:** [10.1371/journal.pmed.1005073](https://doi.org/10.1371%2Fjournal.pmed.1005073)
- **Published At:** 2026-11-17T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The investigators constructed an individual-level stochastic simulation of US gonorrhea diagnosis and treatment to evaluate **resistance-guided therapy** (RGT) strategies. - The model incorporated infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, partner management, and costs reported in 2025 US dollars. - Three testing strategies were examined: ciprofloxacin-only, ciprofloxacin + ceftriaxone, and a triple-target test including a novel drug A; the source described a wide range of resistance scenarios. - Economic value was quantified across three dimensions: per-episode direct medical cost savings; system-level costs attributable to **ceftriaxone** resistance emergence among men who have sex with men (MSM); and avoided costs of new antibiotic development. - Per-episode cost-neutral per-test thresholds varied with resistance prevalence—from near $0 when no ceftriaxone resistance was present to up to $48 per test at 15% ceftriaxone resistance. - For a scenario with 50% ciprofloxacin resistance and 5% ceftriaxone resistance, the population-weighted threshold per test was $7 (95% UI $3-$11) for a ciprofloxacin-only assay and $13 (95% UI $8-$19) for a triple-target assay. - When system-level resistance emergence costs and avoided antibiotic development costs were included for MSM, per-test value rose substantially (single-target $31–$114; triple-target $73–$106), depending on assumptions about prescribing changes at 5% ceftriaxone resistance. - The authors noted main limitations: the model assumed resistance results were available at the same visit to guide initial treatment, did not model onward transmission or co-resistance, and could estimate longer-term value only for MSM.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43043955/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43043955/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43043955/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43043955/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43043955/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43043955/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43043955/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43043955/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43043955/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43043955/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43043955/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43043955/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43043955/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43043955/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/43043955/#conflict-of-interest) Title & authors Abstract Conflict of interest statement PLoS Med Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22PLoS+Med%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22PLoS+Med%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43043955/) . 2026 Nov 17;23(11):e1005073. doi: 10.1371/journal.pmed.1005073. Online ahead of print. # Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study [Brooke E Nichols](https://pubmed.ncbi.nlm.nih.gov/?term=Nichols+BE&cauthor_id=43043955)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#full-view-affiliation-1 "Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#full-view-affiliation-2 "Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands."), [Betsy Wonderly Trainor](https://pubmed.ncbi.nlm.nih.gov/?term=Wonderly+Trainor+B&cauthor_id=43043955)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#full-view-affiliation-3 "CARB-X, Boston University, Boston, Massachusetts, United States of America."), [Grace Hampson](https://pubmed.ncbi.nlm.nih.gov/?term=Hampson+G&cauthor_id=43043955)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#full-view-affiliation-4 "Office of Health Economics, London, England, United Kingdom."), [Yonatan H Grad](https://pubmed.ncbi.nlm.nih.gov/?term=Grad+YH&cauthor_id=43043955)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#full-view-affiliation-5 "Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America."), [Jeffrey D Klausner](https://pubmed.ncbi.nlm.nih.gov/?term=Klausner+JD&cauthor_id=43043955)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#full-view-affiliation-6 "Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.") Affiliations Expand ### Affiliations * 1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America. * 2 Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands. * 3 CARB-X, Boston University, Boston, Massachusetts, United States of America. * 4 Office of Health Economics, London, England, United Kingdom. * 5 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America. * 6 Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America. * PMID: **43043955** * DOI: [ 10.1371/journal.pmed.1005073 ](https://doi.org/10.1371/journal.pmed.1005073) Item in Clipboard # Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study Brooke E Nichols et al. PLoS Med. 2026. Show details Display options Display options Format Abstract PubMed PMID PLoS Med Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22PLoS+Med%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22PLoS+Med%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43043955/) . 2026 Nov 17;23(11):e1005073. doi: 10.1371/journal.pmed.1005073. Online ahead of print. ### Authors [Brooke E Nichols](https://pubmed.ncbi.nlm.nih.gov/?term=Nichols+BE&cauthor_id=43043955)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#short-view-affiliation-1 "Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#short-view-affiliation-2 "Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands."), [Betsy Wonderly Trainor](https://pubmed.ncbi.nlm.nih.gov/?term=Wonderly+Trainor+B&cauthor_id=43043955)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#short-view-affiliation-3 "CARB-X, Boston University, Boston, Massachusetts, United States of America."), [Grace Hampson](https://pubmed.ncbi.nlm.nih.gov/?term=Hampson+G&cauthor_id=43043955)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#short-view-affiliation-4 "Office of Health Economics, London, England, United Kingdom."), [Yonatan H Grad](https://pubmed.ncbi.nlm.nih.gov/?term=Grad+YH&cauthor_id=43043955)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#short-view-affiliation-5 "Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America."), [Jeffrey D Klausner](https://pubmed.ncbi.nlm.nih.gov/?term=Klausner+JD&cauthor_id=43043955)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43043955/#short-view-affiliation-6 "Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.") ### Affiliations * 1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America. * 2 Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands. * 3 CARB-X, Boston University, Boston, Massachusetts, United States of America. * 4 Office of Health Economics, London, England, United Kingdom. * 5 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America. * 6 Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America. * PMID: **43043955** * DOI: [ 10.1371/journal.pmed.1005073 ](https://doi.org/10.1371/journal.pmed.1005073) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Background:** Rising antimicrobial resistance in Neisseria gonorrhoeae threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric) treatment for uncomplicated gonorrhea in the United States. Ciprofloxacin is no longer recommended for empiric use because of widespread resistance, but it is inexpensive, taken orally, and effective against susceptible infections, which a resistance test can identify. In the context of rising resistance, resistance-guided treatment (RGT) may reduce treatment failures, complications, and inappropriate use of last-line agents while slowing resistance emergence and preserving the efficacy of new and existing drugs. Understanding where RGT provides economic value-across near-term cost savings, delayed resistance emergence, and avoided antibiotic development costs-can illuminate the broader case for investing in resistance testing and help guide pricing and reimbursement decisions. **Methods and findings:** We developed an individual-level stochastic simulation model of gonorrhea diagnosis and treatment in the United States, incorporating infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, and partner management (costs in 2025 US dollars[USD]). We evaluated three resistance testing strategies, ciprofloxacin-only, ciprofloxacin + ceftriaxone, and triple-target (including a novel drug A), across a wide range of resistance scenarios. We quantified economic value across three dimensions: (1) per-episode direct medical cost savings, (2) system-level costs attributable to ceftriaxone resistance emergence among men who have sex with men (MSM), and (3) avoided costs of new antibiotic development, estimating the maximum per-test price at which RGT remains cost-neutral. Per-episode cost-neutrality thresholds ranged from near $0 when ceftriaxone resistance was absent to up to $48 per test at 15% prevalence of ceftriaxone resistance (proportion of infections resistant to ceftriaxone). At a prevalence of 50% ciprofloxacin resistance and 5% ceftriaxone resistance, the population-weighted threshold was $7 (95% uncertainty interval [UI] ($3, $11) for a ciprofloxacin-only test and $13 (95% UI [$8-$19]) for a triple-target test. Among MSM, incorporating system-level resistance emergence costs and avoided antibiotic development costs increased the total per-test value to $31 to $114 for a single-target test and $73 to $106 for a triple-target test, depending on whether prescribing practices shift when ceftriaxone resistance reaches 5%. The main limitations are that the model assumes resistance results are available at the same clinical visit to guide initial treatment, does not represent onward transmission or co-resistance between antibiotics, and could estimate longer-term value only for MSM. **Conclusions:** Resistance-guided therapy offers economic benefits across multiple dimensions even at relatively high diagnostic prices, supporting investment in gonorrhea resistance testing to improve partner outcomes, delay resistance emergence, and enhance the long-term cost-efficiency of gonorrhea management. Copyright: © 2026 Nichols et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement I have read the journal’s policy and the authors of this manuscript have the following competing interests: BEN’s institution received support for the work reported in this manuscript from CARB-X. BWT is a paid employee of CARB-X, which provided support for this work. GH is an employee of the Office of Health Economics, which receives funding from a range of public and private sources, including the pharmaceutical industry. YHG reports grants paid to his institution from the National Institutes of Health, the Bill & Melinda Gates Foundation, and GARDP; consulting fees from CARB-X and from Analysis Group/GSK; travel support from the Gates Foundation to attend the Grand Challenges Meeting; and service on the scientific advisory boards of Kanso Diagnostics, Decoy Therapeutics, and Claryx. JDK has declared that no competing interests exist. This does not alter our adherence to the journal’s policies on sharing data and materials. BEN is on Editorial Board. [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/43043955/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/43043955/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/43043955/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/) ![](https://pubmed.ncbi.nlm.nih.gov/stat?HTTP_REFERER=&SELF_URL=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43043955%2F&browserheight=600&browserwidth=1080&colorDepth=24&connection_effectivetype=4g&connection_type=&cookieSize=637&cookieenabled=true&is_browser_supported=true&jsevent=render&jsloadtime=&jsperf_basePage=76&jsperf_connect=0&jsperf_dns=0&jsperf_navTimingNetworkMS=534&jsperf_navTimingRedirectCount=0&jsperf_navTimingType=navigate&jsperf_navType=0&jsperf_redirectCount=0&jsperf_ttfb=459&jsrendertime=&language_code=en-US&log_category=literature&log_displayeduids=43043955&log_op=retrieve&log_source_db=pubmed&myncbi_signed_in=false&ncbi_algorithm=&ncbi_app=pubmed&ncbi_cost_center=pubmed&ncbi_db=pubmed&ncbi_featured_srcdb=&ncbi_nwds=yes&ncbi_nwds_ver=1.2.5&ncbi_pcid=&ncbi_pdid=abstract&ncbi_phid=99A00001784FACC5000041B8583B64E3.1.m_3&ncbi_program=&ncbi
## Related Clinical Research

- [Economic value of gonorrhea resistance testing in the US: cost-neutral price thresholds](https://medichelpline.com/clinical-feed/plos-medicine-0-economic-value-of-gonorrhea-resistance-testing-in-the-united-states-a-multi.md)
- [Bacterial profile and mortality predictors in necrotizing fasciitis — multicentre Uganda study](https://medichelpline.com/clinical-feed/pubmed-43049839.md) (DOI: 10.1007/s15010-026-02767-1)
- [Pharyngeal Gonorrhea vs Urogenital Strains in Ugandan Men: AMR and Genomic Differences](https://medichelpline.com/clinical-feed/pubmed-42415364.md) (DOI: 10.1093/infdis/jiag353)
- [Clinical and epidemiological profile of invasive non-typhoidal Salmonella disease in Ghana](https://medichelpline.com/clinical-feed/plos-one-23-clinical-and-epidemiological-characteristics-of-invasive-non-typhoidal.md)
- [Multidrug-resistant Salmonella in Fruit Bats and Shared Water Sources in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-22-ecology-and-epidemiology-of-multidrug-resistance-salmonella-in-fruit-bats-and.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.